Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5 (4) , 287-292
- https://doi.org/10.3816/cbc.2004.n.032
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human MalignanciesJournal of Clinical Oncology, 2002
- Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effectAnnals of Oncology, 2002
- Weekly docetaxel (Taxotere®) in patients with metastatic breast cancerAnnals of Oncology, 2001
- Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II TrialJournal of Clinical Oncology, 2001
- Does This Patient Have Clubbing?JAMA, 2001
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapyCancer, 1999
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998